Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. Arber DA, et al. Among authors: odenike om. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850. Blood. 2022. PMID: 35767897 Free PMC article.
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, Stock W. Odenike OM, et al. Invest New Drugs. 2008 Jun;26(3):233-9. doi: 10.1007/s10637-008-9115-6. Epub 2008 Jan 24. Invest New Drugs. 2008. PMID: 18217206 Free PMC article. Clinical Trial.
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. O'Donnell PH, et al. Among authors: odenike om. Leuk Lymphoma. 2010 Dec;51(12):2240-9. doi: 10.3109/10428194.2010.520773. Epub 2010 Oct 4. Leuk Lymphoma. 2010. PMID: 20919852 Free PMC article. Clinical Trial.
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology. Gupta P, et al. Among authors: odenike om. Invest New Drugs. 2013 Oct;31(5):1311-20. doi: 10.1007/s10637-013-9978-z. Epub 2013 May 23. Invest New Drugs. 2013. PMID: 23700288 Free PMC article. Clinical Trial.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Roloff GW, et al. Haematologica. 2023 Aug 1;108(8):2234-2239. doi: 10.3324/haematol.2022.282148. Haematologica. 2023. PMID: 36655425 Free PMC article. No abstract available.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Johnston H, Youshanlouei HR, Osei C, Patel AA, DuVall A, Wang P, Wanjari P, Segal J, Venkataraman G, Cheng JX, Gurbuxani S, Lager A, Fitzpatrick C, Thirman M, Nawas M, Liu H, Drazer M, Odenike O, Larson R, Stock W, Saygin C. Johnston H, et al. Blood Adv. 2024 Jan 9;8(1):164-171. doi: 10.1182/bloodadvances.2023011862. Blood Adv. 2024. PMID: 38039510 Free PMC article.
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W. Saygin C, et al. Among authors: odenike om. Blood Cancer Discov. 2024 May 1;5(3):164-179. doi: 10.1158/2643-3230.BCD-23-0106. Blood Cancer Discov. 2024. PMID: 38150184
24 results